Based on the Clene Inc. stock forecast from 1 analysts, the average analyst target price for Clene Inc. is USD 31.00 over the next 12 months. Clene Inc.’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Clene Inc. is Bearish, which is based on 1 positive signals and 8 negative signals. At the last closing, Clene Inc.’s stock price was USD 2.98. Clene Inc.’s stock price has changed by -2.93% over the past week, -28.02% over the past month and -55.26% over the last year.
No recent analyst target price found for Clene Inc.
No recent average analyst rating found for Clene Inc.
Company Overview Clene Inc.
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah. Read Less
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a complete...Read More
Frequently Asked Questions About Clene Inc. (CLNN) Stock
Based on ratings from 1 analysts Clene Inc.'s stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 2 buy, sell and hold ratings.
Unfortunately we do not have enough data on CLNN's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for CLNN is USD 31.00 over the next 12 months. The maximum analyst target price is USD 31 while the minimum anlayst target price is USD 31.
CLNN stock's Price/Earning ratio is 4.41.
Our analysis grades CLNN stock's Price / Earning ratio at A+. This means that CLNN stock's Price/Earning ratio is above 3.000000000000003% of the stocks in the Packaged Foods sector in the NSD exchange.
Based on this CLNN may be undervalued for its sector.
The last closing price of CLNN's stock was USD 2.98.
The most recent market capitalization for CLNN is USD 0.03B.
Based on targets from 1 analysts, the average taret price for CLNN is projected at USD 31.00 over the next 12 months.
This means that CLNN's stock price may go up by +940.27% over the next 12 months.
We can't find any ETFs which contains Clene Inc.'s stock.
As per our most recent records Clene Inc. has 75 Employees.
Clene Inc.'s registered address is 6550 South Millrock Drive, Salt Lake City, UT, United States, 84121.
You can get more information about it from Clene Inc.'s website at https://clene.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Underpriced compared to earnings
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Clene Inc. (CLNN) Stock
Based on ratings from 1 analysts Clene Inc.'s stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 2 buy, sell and hold ratings.
Unfortunately we do not have enough data on CLNN's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for CLNN is USD 31.00 over the next 12 months. The maximum analyst target price is USD 31 while the minimum anlayst target price is USD 31.
CLNN stock's Price/Earning ratio is 4.41.
Our analysis grades CLNN stock's Price / Earning ratio at A+. This means that CLNN stock's Price/Earning ratio is above 3.000000000000003% of the stocks in the Packaged Foods sector in the NSD exchange.
Based on this CLNN may be undervalued for its sector.
The last closing price of CLNN's stock was USD 2.98.
The most recent market capitalization for CLNN is USD 0.03B.
Based on targets from 1 analysts, the average taret price for CLNN is projected at USD 31.00 over the next 12 months.
This means that CLNN's stock price may go up by +940.27% over the next 12 months.
We can't find any ETFs which contains Clene Inc.'s stock.
As per our most recent records Clene Inc. has 75 Employees.
Clene Inc.'s registered address is 6550 South Millrock Drive, Salt Lake City, UT, United States, 84121.
You can get more information about it from Clene Inc.'s website at https://clene.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for CLNN !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
